Record mula sa primary source
Decision-gradePag-apruba ng FDA
Inaprubahan ng FDA ang AbbVie SKYRIZI (risankizumab-rzaa) para sa pediatric psoriatic disease
FDA approved SKYRIZI for children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, including a new 55 mg pre-filled syringe for weight-based dosing in patients <40 kg. SKYRIZI is now the first and only IL-23 inhibitor approved in the U.S. for this pediatric population.
Mahahalagang fact
- Na-file
- Okt 30, 2026, 11:51 AM
- Kaganapan
- Pag-apruba ng FDA
- Direksyon
- Positibo
- Kumpanya
ABBVAbbVie- Asset
- risankizumab
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease News provided by AbbVie Jun 26, 2026, 16:50 ET Share this article Share to X Share this article Share to X SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis NORTH CHICAGO, Ill. , June 26, 2026 /PRN
Higit pa tungkol sa asset na ito
Okt 24, 2026
03:33 AM
ABBVAbbVieOkt 17, 2026
02:00 PM
ABBVAbbVieIpinapakita ng AbbVie ang pangmatagalang data ng SKYRIZI at RINVOQ para sa IBD sa UEGW 2026
Okt 14, 2026
03:15 AM
ABBVAbbVieIpinapakita ng AbbVie ang Data ng Phase 3 AFFIRM Subcutaneous SKYRIZI sa ACG 2026 sa Sakit na Crohn
Okt 12, 2026
01:00 AM
ABBVAbbVieIpinapakita ng AbbVie ang bagong datos ng Phase 3 AFFIRM at pangmatagalang FORTIFY para sa SKYRIZI sa sakit na Crohn sa ACG 2026
Ago 27, 2026
06:00 AM
ABBVAbbVieHun 23, 2026
07:00 AM
ABBVAbbVie